ML 315 hydrochloride is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research.

STM2120 is a METTL3-METTL14 inhibitor with an IC50 of 64.5 μM.

Martinostat is a histone deacetylase imaging agent.

Martinostat (hydrochloride) is a inhibitor of HDAC that can be labeled with radionuclides for diagnostic applications.

Potent TIR1 antagonist, blocking the formation of the TIR1-IAA-Aux/IAA complex and so inhibiting auxin-responsive gene expressionReferences:1) Smékalová V, Luptovčiak I, Komis G, Šamajová O, Ovečka M, Doskočilová A, Takáč T, Vadovič P, Novák O, Pechan T,

Novel inhibitor of SIRT6, sensitizing pancreatic cancer cells to gemcitabineREFERENCES1) Damonte P, Sociali G, Parenti MD, Soncini D, Bauer I, Boero S, Grozio A, Holtey MV, Piacente F, Becherini P, Sanguineti R, Salis A, Damonte G, Cea M, Murone M, Poggi

OTS514 hydrochloride is a highly potent TOPK inhibitor, which inhibits TOPK kinase activity with a median inhibitory concentration (IC50) value of 2.6 nM. OTS514 hydrochloride strongly suppresses the growth of TOPK-positive cancer cells. OTS514 hydrochloride induces cell cycle arrest and apoptosis.

Robenacoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in veterinary medicine for the relief of pain and inflammation in cats and dogs, a Cyclooxygenase(COX)-1 and COX-2 inhibitor..

SR1078 is an agonist of retinoic acid receptor-related orphan receptors (ROR) RORα/γ.

Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.

Antibacterial agent 125 is an antibacterial agent. Antibacterial agent 125 has a potent antimicrobial activity against clinically relevant Gram-positive pathogens with MIC50 values range from 0.25 - 8 μM. Antibacterial agent 125 can be used for the research of antimicrobial resistance.

Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.

CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain.

GSK-3b inhibitors; GSK-3b inhibitors;

Lalistat 2 is a specific inhibitor of lysosomal acid lipase (LAL) with no effect on other forms of lipase.

GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein[1].

OUL35 (NSC39047) is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of 330 nM, displays remarkable selectivity towards ARTD10 over other enzymes in the human protein family.

IGF-1R/SRC inhibitor

useful for the treatment of cystic fibrosis; modulating CFTR activity; altering the lifespan of a eukaryotic organism;

cytotoxity (targeted to DNA topoisomerase II); anti-cancer activity; fungicides;

VEGF inhibitor

6-Maleimidocaproic acid contains a maleimide group and a terminal carboxylic acid. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or DCC) to form a stable amide bond. The maleimide group will react with a thiol group to form a covalent bond, enabling the connection of biomolecule with a thiol.

NOX-6-18 is a potent, selective GPR132 antagonist with IC50 of 17 nM.

CPI-360 is a compound in design and preparation of wew palladium precatalysts for C-C and C-N cross-coupling reactions.

BMS-P5 is a Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor with pIC50 values in the range of 5-​7.5. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma.

Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.

glucocerebrosidase activator;

anti-inflammatory, COX inhibitory activities and ulcerogenic liability